An Open-label, Non-randomised, Multicentre, Comparative, Phase I Study to Determine the Pharmacokinetics, Safety and Tolerability of Olaparib Following a Single Oral 300 mg Dose to Patients With Advanced Solid Tumours and Normal Hepatic Function or Mild or Moderate Hepatic Impairment
Phase of Trial: Phase I
Latest Information Update: 16 Sep 2019
Price : $35 *
At a glance
- Drugs Olaparib (Primary)
- Indications Liver cancer; Liver metastases; Solid tumours
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 24 Mar 2017 Status changed from active, no longer recruiting to completed.
- 18 Mar 2017 Results (n=67) assessing pharmacokinetics and safety of olaparib using patient data from NCT01894256 and NCT01894243 trials, presented at the 118th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 31 Jan 2017 Planned End Date changed from 1 Jan 2018 to 1 Dec 2017.